Full text is available at the source.
Abstract
Obesity is associated with increased frequency and severity of migraine attacks.
- Glucagon-like peptide-1 (GLP-1) receptor agonists may offer benefits beyond controlling blood sugar and managing weight.
- Emerging evidence suggests GLP-1 medications could assist in pain modulation.
- Clinical observations indicate a potential role for GLP-1 therapies in treating idiopathic intracranial hypertension.
- The specific effects of GLP-1 based treatments on migraine have not yet been established.
Simplified